← Back to Clinical Trials
Recruiting NCT06951438

NCT06951438 Assessing Acceptability and Feasibiity of STI Self-swab Testing, to be Offered at the Time of Telemed Medication Abortion Provision

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06951438
Status Recruiting
Phase
Sponsor Queen's Medical Center
Condition Sexually Transmitted Disease (STD)
Study Type INTERVENTIONAL
Enrollment 75 participants
Start Date 2025-05-22
Primary Completion 2026-04-30

Trial Parameters

Condition Sexually Transmitted Disease (STD)
Sponsor Queen's Medical Center
Study Type INTERVENTIONAL
Phase N/A
Enrollment 75
Sex FEMALE
Min Age 14 Years
Max Age N/A
Start Date 2025-05-22
Completion 2026-04-30
Interventions
Self-swab collection PCR test for chlamydia, gonorrhea, trichomonas

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The goal of this interventional study is to provide more access to STI testing for patients who seek abortion care through telemedicine, particularly for those whose access to STI testing is otherwise limited. The main questions it aims to answer are: What is the acceptability, feasibility, and utilization of self-collected STI screening at the time of telemedicine medication abortion provision? How does the uptake of such a service among patients receiving telemedicine abortion care compare to the population of patients who seek in-person medication abortion care? What are the positivity rates for STIs in among patients receiving telemedicine medication abortion care compared to the positivity rates for a contemporaneous, in-clinic population? What is the average time to between testing and treatment for patients who test positive for an STI using the self-collection service? Researchers will compare the intervention group to a contemporaneous, in-clinic population on uptake of STI screening, as well as on positivity rates for the STIs tested. Participants will be asked to perform self-swab collection for STI testing for gonorrhea, chlamydia, and trichomonas. They will be instructed to send their specimens to a lab using prepaid postage. Upon completion of sample collection and shipping, they will be asked to complete a survey assessing basic demographic information, as well as acceptability and feasibility of the intervention. Patients who test positive for an STI will be promptly provided/referred to treatment.

Eligibility Criteria

Inclusion Criteria: 1. Patients of the Queen Medical Center Options Center clinic seeking telemedicine medication abortion. 2. Patients for whom, according to the CDC guidelines for STI Testing11, STI testing is indicated, or patients who desire STI screening 3. Age 14 and over 4. Can speak and read English 5. Displays capacity for informed consent Exclusion Criteria: 1. Home address that is not located in the state of Hawai'i 2. Incarcerated 3. Unwilling to perform vaginal swab collection

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology